Dayer, Victoria W. http://orcid.org/0000-0002-0188-4237
Drummond, Michael F.
Dabbous, Omar
Toumi, Mondher
Neumann, Peter
Tunis, Sean
Teich, Nelson
Saleh, Shadi
Persson, Ulf
von der Schulenburg, Johann-Matthias Graf
Malone, Daniel C.
Salimullah, Tay
Sullivan, Sean D.
Funding for this research was provided by:
Novartis Gene Therapies, Inc. (Novartis Gene Therapies, Inc.)
Article History
Received: 24 July 2023
Accepted: 19 January 2024
First Online: 7 February 2024
Declarations
:
: The manuscript does not contain clinical studies or patient data.
: Not applicable.
: VWD, MFD, and SDS received research support and served as consultants to Novartis Gene Therapies, Inc. SDS also served as a consultant/on an advisory board for Bayer US. MFD received an unrestricted grant from Roche, through Bocconi University to study HTA bodies’ responses to the analytic challenges posed by cell and gene therapies. MT received consulting fees from Novartis Gene Therapies, Inc. PN is employed by the Tufts Center for the Evaluation of Value and Risk in Health, which maintains a variety of databases that are sponsored by life sciences companies, government agencies, and academic institutions. He also reports grants from NPC, NIH, the Alzheimer’s Association, Arnold Ventures, BMS, Otsuka, and Travere; funding to The CEA registry from NSF, NLM, AHRQ, the CDC, and a variety of pharmaceutical and device companies and non-profits which subscribe to the data (ExternalRef removed); personal fees from CBO, Bayer, Panalgo, Merck, ArgenX, and Novartis Gene Therapies, Inc., and Sarepta (consulting). ST received honoraria from Novartis Gene Therapies, Inc., for conducting the ForGHE study and participation in the ForGHE advisory board. He also received fees for advisory board participation from BioMarin and UCB Pharma. NT has stock and other ownership interests in Clover Biopharmaceuticals and 4D PATH, has received honoraria from Novartis and Clover Biopharmaceuticals, and served in a consultant/advisory role for Novartis, 4D PATH, and Clover Biopharmaceuticals. SS has received consulting fees from Novartis Gene Therapies, Inc. UP has no relevant financial or non-financial interests to disclose. J-MGvdS is a consultant for Novartis Gene Therapies, Inc. DCM served as a consultant for Novartis, Novartis Gene Therapies, Inc., Sarepta, Pharmacyclics, Currax, and Seres, and served on advisory boards for BioMarin and Novartis. OD and TS are employees of Novartis Gene Therapies, Inc., and own stock and other equities.